The obesity wars just got spicier.
Today, just a month after Pfizer said it would buy Metsera, Novo Nordisk swooped in with its own bid. Metsera says Novo’s offer is “superior.” Pfizer says it’s not allowed under their terms.
On Post-Hoc Live today I spoke with BMO's Head of Healthcare Research Evan Seigerman, and our own biotech deals reporter Kyle LaHucik. We got into what we know, what we’re watching, and where we think this goes next.
Subscribe on YouTube to get alerts about our next show. Tomorrow we'll be talking with Rebecca Ahrens-Nicklas, a pediatrician and gene therapy scientist at CHOP, and Kiran Musunuru, a UPenn gene editing scientist, about their work creating n-of-1 gene therapies, and how they hope to scale that model.
Thanks for watching!
— Drew
↧